Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
40200811 (PubMed )
Supplement: cbm-22-237-s001.pdf
The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
Moorthi S et al.
Jci Insight, 2024
39052387 (PubMed )
Supplement: jciinsight-9-174643-s252.xlsx › Table_S3
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
Zhu J et al.
Lung Cancer (auckland, N.z.), 2024
Identification and molecular analysis of RNF31 Q622H germline polymorphism.
Nakazawa S et al.
Oncology Letters, 2022
36276481 (PubMed )
Supplement: Supplementary_Data2.pdf
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Wiesweg M et al.
Lung Cancer (amsterdam, Netherlands), 2020
Select a paper to view details